Li et al. also reported that BrMs of lung cancers had reduced tumor infiltrating lymphocytes, decreased scores of immune-related signatures, and a lower proportion of tumors with high PD-L1/high CD8A [28]. The gene discussed is CD8A; the disease is lung carcinoma.